Cardiometabolic & kidneySecondary analysis
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
- Secondary analysis of the FLOW randomised trial
- prespecified analysis
Heart failure (HF) data collected by the investigator; Cardiovascular (CV) death adjudicated by an independent committee
Authors' conclusion
Semaglutide substantially reduced the risk of time to first composite outcome of HF events or CV death, as well as HF events and CV death alone, in a high-risk population with T2D and CKD.
Study context
- Population
- People with T2DM and chronic kidney disease (CKD)
- Participants
- 3,533 people
- Comparison
- Semaglutide vs placebo
- Primary endpoint
- Composite of:
- HF events (new onset or worsening HF leading to unscheduled hospital admission or urgent visit, with initiated or intensified diuretic/vasoactive therapy)
- CV death
- Follow-up
- Median 3.4 years
Primary result
As reported in the abstract
Hazard ratio
0.73
95% CI 0.62–0.87
P = 0.0005
Semaglutide vs Placebo
HR 0.73 (95% CI 0.62–0.87); P = 0.0005
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| HF events alone | 0.73 (0.58–0.92) | P = 0.0068 | |
| CV death alone | 0.71 (0.56–0.89) | P = 0.0036 | |
| Composite HF outcome, by HF at baseline (subgroup) — Semaglutide vs Placebo · with HF at baseline | 0.73 (0.54–0.98) | P = 0.0338 | |
| Composite HF outcome, by HF at baseline (subgroup) — Semaglutide vs Placebo · without HF at baseline | 0.72 (0.58–0.89) | P = 0.0028 | |
| 0.512Hazard ratio (log scale) |
HF outcomes (HF events or CV death) by NYHA class and HF subtype
- Risk generally higher in NYHA class III and HFrEF, regardless of treatment
Original publication
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J Am Coll Cardiol. Published 30 August 2024. doi:10.1016/j.jacc.2024.08.004
Summarised from the published abstract; every number is checked against it